Investors & Media

Ionis’ partner to evaluate tominersen for Huntington’s disease in new Phase 2 trial

– Post-hoc analysis of GENERATION HD1 study data showed tominersen may have potential benefit in a subgroup of patients – Ionis’ partner Roche is in early stages of designing trial for younger adult patient population with less disease burden – Partner to participate in series of webinars for

Read more
You are now leaving to visit